EUVIMEDSkopri EUVIMED
Open access · CC BY-NC 3.0

Doxorubicin and Edelfosine Combo-Loaded Lipid–Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma [Retraction]

Ping Yang, Lian Zhang, Tian Wang, Qi Liu, Jing Wang, Yaling Wang, Zhiquan Tu, Feng Lin

OncoTargets and Therapy · 2026-04 · Volume 19 · 1-1

DOI: 10.2147/ott.s614697 ↗

At a glance

Journal article in OncoTargets and Therapy, 2026-04. Written by Ping Yang and 7 co-authors. The full text is freely available (open access, CC BY-NC 3.0).

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Ebda abstract disponibbli.

Cite

APA

Yang, P., Zhang, L., Wang, T., Liu, Q., Wang, J., Wang, Y., Tu, Z., & Lin, F. (2026). Doxorubicin and Edelfosine Combo-Loaded Lipid–Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma [Retraction]. OncoTargets and Therapy, Volume 19, 1-1. https://doi.org/10.2147/ott.s614697

Vancouver

Yang P, Zhang L, Wang T, Liu Q, Wang J, Wang Y, et al. Doxorubicin and Edelfosine Combo-Loaded Lipid–Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma [Retraction]. OncoTargets and Therapy. 2026;Volume 19:1-1. doi:10.2147/ott.s614697

BibTeX
@article{Yang2026,
  author = {Yang, Ping and Zhang, Lian and Wang, Tian and Liu, Qi and Wang, Jing and Wang, Yaling and Tu, Zhiquan and Lin, Feng},
  title = {Doxorubicin and Edelfosine Combo-Loaded Lipid–Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma [Retraction]},
  journal = {OncoTargets and Therapy},
  year = {2026},
  volume = {Volume 19},
  pages = {1--1},
  doi = {10.2147/ott.s614697}
}
Start for free →